Biomedica Sclerostin ELISA

Click2Contact

Canonical Wnt signalling plays an important role in the regulation of bone homeostasis by promoting the development of osteoblasts. Negative regulators of the Wnt pathway are important new therapeutic targets for the treatment of diseases with enhanced bone resorption. One of these molecules is Sclerostin, a 22.5 kD secreted glycoprotein, which acts by binding to the Wnt-coreceptor LRP5 thus preventing the binding of Wnt molecules. Sclerostin is nearly exclusively produced in osteocytes; therefore, it is considered a clinical marker which provides highest bone specificity.

The measurement of serum sclerostin levels is a novel approach in studying the regulation of bone mass and may serve as a tool in detecting bone disorders and monitoring the efficiency of various therapies. Areas of related research include osteoporosis, cancer-induced bone diseases, rheumatoid arthritis, chronic inflammation, kidney disease and therapy monitoring of anabolic treatment.

The Sclerostin ELISA from Biomedica is a highly sensitive ELISA for the measurement of human samples as small as 20 µL. The kit includes all necessary reagents, including standards and control, and has a convenient ready-to-use protocol.